Genus plc (GNS) Fair Value & Analysis
Healthcare · GB · Market cap 1.5B GBX
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price −8.7% over the past month.
Price vs Fair Value (12 months)
12‑month range £19.58 – £31.33 · fair‑value band £3.93 – £7.99 · the £21.10 price screens above the £6.39 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Genus plc (GNS) currently trades at £21.10, while our model-based Fair Value estimate is £6.39 — implying the stock looks roughly 69.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Genus plc generated revenue of £672M at a net margin of 7.1%. Revenue declined 0.2% year over year. It earns a return on equity of 9.4%. Net debt stands at £218M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Genus plc reported revenue of £673M in FY2025 versus £574M in FY2021, a compound +4.0%/yr. Reported net income was £19.3M in FY2025, compounding −20.1%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$607.20 | R$74.60 | -88% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Genus plc (GNS) undervalued?
What is the fair value of GNS?
What is the quality score of GNS?
What is the revenue of Genus plc (GNS)?
What is the net profit margin of GNS?
Does Genus plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.